Published Date: 02 Mar 2023
A link between depression and changes in various immune systems in the blood has been discovered by researchers from the Department of Integrative Epidemiology at MRC, University of Bristol. The results of this research...
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer
2.
Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation
3.
The White House has postponed its plan to outlaw menthol cigarettes indefinitely.
4.
No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma
5.
In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".
1.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
2.
Targeting Oncology: Expanding Combinatorial Strategies by 2025
3.
The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment
4.
Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development
5.
Single-Cell Lineage Tracing in Hematology: Decoding the Cellular Blueprint of Blood Disorders
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation